Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) is expected to be announcing its Q4 2024 earnings results before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($2.76) per share and revenue of $0.36 million for the quarter.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Stock Down 40.6 %

NASDAQ:PRAX traded down $26.43 on Friday, hitting $38.60. The stock had a trading volume of 3,199,803 shares, compared to its average volume of 452,800. Praxis Precision Medicines has a 52 week low of $33.01 and a 52 week high of $91.83. The business's fifty day moving average is $76.99 and its 200 day moving average is $69.63. The company has a market cap of $719.43 million, a PE ratio of -3.75 and a beta of 2.65.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PRAX. Oppenheimer lifted their price objective on shares of Praxis Precision Medicines from $143.00 to $163.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and set a $150.00 price target on shares of Praxis Precision Medicines in a research note on Monday, February 10th. HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Praxis Precision Medicines in a report on Thursday, December 12th. Truist Financial raised their target price on Praxis Precision Medicines from $150.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft began coverage on Praxis Precision Medicines in a research report on Tuesday, February 11th. They set a "buy" rating and a $111.00 target price on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Praxis Precision Medicines has an average rating of "Moderate Buy" and an average price target of $145.20.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.